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Dear Secretary of State, 
 
The Advisory Council on the Misuse of Drugs (ACMD) wrote to the Home Office 
in January 2008 and advised that the ACMD considered it expedient to provide 
you with a report on its consideration of anabolic steroid misuse. I have pleasure 
in enclosing a report on the ‘Consideration of the Anabolic Steroids’.    
 
The report has recommendations that are cross cutting and that will be relevant 
to policy areas in a number of government departments, particularly the Home 
Office and the Department of Health.  
 
The enclosed report came about following the ACMD’s increasing concerns at 
the use of anabolic steroids by the general public, and in particular young people. 
These substances have become ‘popular’ in relation to body building and image 
enhancement and there is some evidence that such use is increasing. 
 
The purpose of the report was to consider the evidence of harms and provide 
advice on potential harm reduction mechanisms. The ACMD set out to consider 
the available evidence regarding anabolic steroid use/misuse, physical and social 
harms. The working group placed particular emphasis on the level of use/misuse 
among young people. 
 
3Although the focus of the report is the misuse and harms of anabolic steroids in 
the general public, the report acknowledges that anabolic steroids have been 
used by sportspeople in a number of well publicised cases and makes reference 
to this form of use.  
 
After considering the available evidence the ACMD recommend that - based on 
their harmfulness to individuals and society - anabolic steroids should continue to 
be controlled as Class C drugs under the Misuse of Drugs Act 1971. In addition, 
it is recommended that there continues to be no possession offence for personal 
use.  
 
The ACMD recommend that the legal framework is strengthened so as to prevent 
importation of anabolic steroids not intended for medical use and that there is a 
greater emphasis placed upon education and interventions.  
 
The report includes a number of research recommendations – the focus should 
be to obtain better information on prevalence and user demographics to inform 
interventions.   
 
The production of this report has been greatly aided by valuable contributions 
from a wide range of organisations and experts. The ACMD is particularly 
grateful to those experts who provided written and oral evidence to the Working 
Group.  
 
Yours sincerely  
Professor Les Iversen 
 
Cc:  
Simon Burns MP - Minister of State for Health 
James Brokenshire MP - Parliamentary under Secretary of State for Crime 
Reduction (Home Office) 
Anne Milton MP - Parliamentary Under Secretary of State for Health 
Edwina Hart MBE AM; Minister for Health and Social Services (Welsh Assembly) 
Nicole Sturgeon MSP- Deputy First Minister of Scotland, Cabinet Secretary for 
Health and Wellbeing  
Michael McGimpsey - Minister of Health, Social Services and Public Safety 
(Northern Ireland) 
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5Executive Summary  
 
The ACMD consider that this report on anabolic steroids is timely due to its 
concerns regarding the harms of their use and the evidence that use of is 
increasing. The report provides recommendations concerned with harm 
reduction, the legislative framework and research. The report has a particular 
focus on use by young people.   
 
Anabolic steroids are synthetic substances which are related to the male sex 
hormones, particularly testosterone. These substances have a number of 
physiological effects, most notably anabolic effects and androgenic effects. 
 
The ACMD found that it remains difficult to determine how many people use 
anabolic steroids for non-medical reasons. The most comprehensive data on 
drug misuse for England and Wales are provided by the British Crime Survey 
which estimates that in the 16-59 year old age group around 226,000 people 
admitted to “ever” having used anabolic steroids, with 50,000 users in the past 
year, and 19,000 in the past month (Hoare and Moon, 2010).  
 
The ACMD report a range of potential harms associated with the use of anabolic 
steroids; these include acne, cardiovascular symptoms, psychological (e.g. 
aggression, violence and hypomania) and hepatic dysfunction. In particular, 
harms to young people from the use of anabolic steroids can lead to virilization 
and potentially disrupt the normal pattern of growth and behavioural maturation.  
 
The report considers the issue of substandard and counterfeit anabolic steroids, 
and outlines the potential harms associated with these.   
 
The ACMD found in a recent report by the National Treatment Agency for 
Substance Misuse, that they note some [local drug partnerships] had seen an 
exponential rise in steroid use in recent years. In order to prevent the 
transmission of blood borne viruses, the ACMD recognises that drug users 
should have access to sterile injecting equipment.   
 
The ACMD recommends anabolic steroids should continue to be controlled as 
Class C drugs under the Misuse of Drugs Act 1971. The ACMD considers the 
evidence base regarding the harms of anabolic steroids does not support a 
change in classification status. However, the ACMD recommends further 
restrictions should (if compliant with EU legislation) be placed on the importation 
(and exportation) exemption, namely personal custody on importation.  
 
The ACMD recommends further restriction should (if compliant with EU 
legislation) be placed on the importation (and exportation) exemption, namely 
personal custody on importation; further the ACMD believes the term ‘medicinal 
product’ should be considered for removal from the legislation. The ACMD 
6consider that the term ‘medicinal product’ is now in need of revision as it believes 
that the term causes confusion 
 
The ACMD further believes there is a need for widespread, credible, information 
and advice for users to counteract mis-information provided by various web sites 
that actively promote anabolic steroid use.   
71. Background 
 
1.1 The Advisory Council on the Misuse of Drugs (ACMD) is established 
under the Misuse of Drugs Act 1971. The ACMD’s current membership is 
shown in Annex A. Additional experts also attended the ACMD’s meetings 
to assist in the preparation of this report (Annex B). 
1.2 The ACMD is required under the Misuse of Drugs Act 1971 “to keep under 
review the situation in the United Kingdom with respect to drugs which 
appear to them likely to be misused and of which the misuse is having or 
appears to them of having effects sufficient to constitute a social problem”.
1.3 Substances that are controlled under the Misuse of Drugs Act 1971 are 
grouped into one of three classes;  
• Class A includes cocaine, diamorphine (heroin), 3, 4-
methylenedioxymethylamphetamine (‘ecstasy’), lysergic acid 
diethylamide (LSD), and methylamphetamine. 
• Class B includes amphetamine, barbiturates, cannabis, codeine 
and methylphenidate. 
• Class C includes benzodiazepines, buprenorphine, anabolic 
steroids, gamma-hydroxybutyrate (GHB) and ketamine. 
 
1.4 This system of classification serves to determine the penalties for the 
possession and supply of controlled substances. The current maximum 
penalties are as follows:  
 
• Class A drugs: For possession – up to 7 years’ imprisonment 
and/or an unlimited fine; for supply – up to life imprisonment and/or 
fine. 
• Class B drugs: For possession – up to 5 years’ imprisonment 
and/or an unlimited fine; for supply – up to14 years’ imprisonment 
and/or fine. 
• Class C drugs: For possession – up to 2 years’ imprisonment 
and/or an unlimited fine; for supply – up to 14 years’ imprisonment 
and/or fine. 
 
82. Previous consideration of the Advisory Council on the Misuse 
of Drugs 
 
2.1 Following the ACMD’s consideration of anabolic steroids in January 1993, 
in November 1994 the Home Secretary accepted the advice of the ACMD 
and confirmed that anabolic steroids would be brought under the control of 
the Misuse of Drugs Act as Class C drugs under Part III of Schedule 2 
of the Misuse of Drugs Act 1971. They would also be subject to 
Schedule 4 of the Misuse of Drugs Regulations, but with additional 
import/export restrictions. It was to be an offence under the Act to 
produce, supply or possess/import/export with intent to supply without a 
licence. 
2.2 In line with ACMD’s advice, it is not to be an offence under the Act to 
simply possess anabolic steroids when in the form of a ‘medicinal 
product’1. Article 1 of Directive 2001/83/EC as amended defines a 
“medicinal product” as: 
(a) “Any substance or combination of substances presented as having 
properties for treating or preventing disease in human beings; [“the first 
limb”]. 
 
(b) Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or 
modifying physiological functions by exerting a pharmacological, 
immunological or metabolic action, or to making a medical 
diagnosis” [“the second limb”]. 
 
2.3 Changes to the definition which came into effect from 30 October 2005 are 
shown in bold to aid identification. Medicinal products may well fall under 
both limbs of the definition but the European Court of Justice has 
confirmed that falling under either limb is sufficient to classify a product as 
a medicinal product (Upjohn 1989 C-112/89): “Directive 65/65 (now 
Directive 2001/83) provides two definitions of the term “medicinal product”: 
one relating to presentation, the other to function. A product is medicinal if 
it falls within either of those definitions.” 
 
1 According to the Misuse of Drugs Regulations 2001 ‘“medicinal product” has the same meaning 
as in the Medicines Act 1968(f)’ which is different from Directive 2001/83/EC. Either way it would 
still, subject to the interpretation by the Courts, be likely that substandard and counterfeit products 
be viewed as 'medicinal products', meaning that drug products manufactured in clandestine labs 
should be regarded as medicinal products. However, perhaps this section should reflect what is 
stated in the Misuse of Drugs Regulations 2001. See the following reference for a discussion: 
King, 2009. Forensic chemistry of substance misuse. A guide to drug control. RSC Publishing. p. 
89-90. 
 
92.4 In the absence of a simple possession offence, it was therefore 
considered to be anomalous and contrary to EU restrictions to make the 
importation or exportation of the substances for personal use an offence 
i.e. to have a stricter regime of controls at ports. Permitting importation for 
personal use was consistent with permitting simple possession inland. 
However, in all other circumstances importation and exportation would 
require Home Office authority, and such activity without a licence would be 
an offence.  
 
2.5 In April 2008, the ACMD separately recommended that an additional 15 
anabolic steroids and 2 non-steroidal substances be controlled under the 
Misuse of Drugs Act 1971. This advice was subsequently accepted by 
government; http://www.homeoffice.gov.uk/about-us/home-office-
circulars/circulars-2009/021-2009/21-2009?view=Binary
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3. Introduction  
 
3.1 In November 2007, the Advisory Council on the Misuse of Drugs (ACMD) 
agreed that it would convene a specific working group to further consider 
its concerns around anabolic steroid misuse, particularly among young 
people. The ACMD wrote to the Secretaries of State at the Home Office, 
Department of Health, (the then) Department for Children, Schools and 
Families, Department for Culture, Media and Sport and the Minister for the 
Olympics, outlining the ACMD’s concerns. The ACMD’s correspondence 
cited the British Crime Survey of 2006/07 that estimated that 32,000 adults 
had used anabolic steroids in the last year and 14,000 in the last month 
(Drug Misuse Declared: Home Office Statistical Bulletin 18/07). Figures 
from the Department of Health’s Smoking, Drinking and Drug Use Survey 
(2006) had shown a steady increase in the number of young people that 
had “ever” tried anabolic steroids from 0.2% in 2001-2004 to 0.3% in 
2004/05 and 0.5% in 2006. 
 
3.2 Anabolic steroids are synthetic substances which are related to the male 
sex hormones, particularly testosterone. These substances have a 
number of physiological effects, most notably anabolic effects (such as 
growth of skeletal muscle and bone) and androgenic effects (the 
differentiation, growth and maintenance of the reproductive system and 
sexual characteristics in males). The correct term to describe anabolic 
steroids is anabolic-androgenic steroids; however, they are commonly 
referred to as anabolic steroids.   
 
3.3 Testosterone was initially isolated, characterised and synthesised in 1935. 
Subsequently a large number of congeners (related chemicals, e.g., 
elements in the same group of the periodic table, or derivatives thereof) 
have been synthesised. Some of these substances entered clinical use 
and have been used to treat conditions such as male hypogonadism, 
anaemia, to stimulate bone growth and to treat chronic muscle wasting 
conditions.   
 
3.4 During the evidence gathering for this report the ACMD heard evidence 
from a range of experts about the harms associated with the self-
administration of anabolic steroids (see Annex E) 
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4. Scope 
 
4.1 The purpose of this report is to provide ministers with advice on anabolic 
steroids and associated harm reduction. The ACMD’s remit, outlined in the 
Misuse of Drugs Act 1971, requires it to consider drugs in relation to their 
misuse and harms, both physical and social. The recommendations in this 
report are focussed solely on the misuse and harms of anabolic steroids in 
broader society - outside of their misuse in elite sport.  However, the 
ACMD acknowledges this form of use (see chapter 12).   
 
4.2 The ACMD has previously been requested by the Department of Culture, 
Media and Sport to consider ‘The World Anti-Doping Code –The 2007 
Prohibited List’. The recommendations concerning the WADA (The World 
Anti-Doping Agency) list are published on the ACMD website (see 2.5- link 
above).  
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5. Legislation  
 
United Kingdom 
5.1  Anabolic steroids are controlled as Class C substances under the Misuse 
of Drugs Act 1971, and scheduled under Schedule 4 Part II of the Misuse 
of Drugs Regulations 2001, both as named compounds (of which there are 
currently 69) and using a generic definition. The esters and ethers thereof 
are also controlled. The related drugs Clenbuterol (a Q2-adrenergic 
agonist), Zeranol (nonsteroidal oestrogen), Zilpaterol (a Q2-adrenergic 
agonist), Somatotropin (growth hormone of human origin), Somatrem (a 
synthetic analogue of human growth hormone), Somatropin (synthetic 
human growth hormone), [Human] Chorionic Gonadotrophin (HCG) and 
non-human chorionic gonadotrophin are also controlled. The 
stereoisomeric forms, salts, and related preparations and products of all 
these substances are also controlled. 
 
5.2  Anabolic steroids have limited legitimate use in the UK. Clinically, their 
main use is in the treatment of male hypogonadism (where patients fail to 
produce sufficient levels of testosterone). They are prescription only 
medicines and can only be lawfully sold or supplied in accordance with a 
prescription from an appropriate practitioner. It is legal to possess or 
import/export anabolic steroids as long as they are intended for personal 
use and in the form of a medicinal product. However, the possession or 
import/export with intent to supply, supply, and manufacture is illegal 
unless authorised by a licence of the Secretary of State and could lead to 
14 years in prison and an unlimited fine. 
 
5.3  The definition of ‘medicinal product’ is one that appears to have caused 
confusion, particularly among users and enforcement. The ACMD has 
discussed the definition of ‘medicinal product’ which is defined in the 
Medicines Act 1968 and whether it has been harmonised to the current 
definition used in medicine law afforded by European Directive 
2001/83/EC. Further, such definitional uncertainty has implications for 
personal possession offences where there is confusion between applying 
the term ‘medicinal product’ to only those substances that have received a 
marketing authorisation (i.e. to the exclusion of counterfeit products) or 
whether it should be applied in terms of the directive, i.e.: 
 
(a) Any substance or combination of substances presented as 
having properties for treating or preventing disease in human 
beings; or 
 
(b) Any substance or combination of substances which may be 
used in or administered to human beings either with a view to 
restoring, correcting or modifying physiological functions by exerting 
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a pharmacological, immunological or metabolic action, or to making 
a medical diagnosis. 
 
5.4  From a public health perspective the confusion could act as a barrier and 
prevent users from engaging with health services: some users may think 
that the steroids they possess are unlawful as they are not ‘medicinal 
products' (i.e. not legitimate as they have not been granted a marketing 
authorisation and/or might be counterfeits). Moreover, for enforcement, the 
application of a strict definition of a medicinal product (i.e. one with 
marketing authorisation) may lead to prosecution of those who are 
believed to possess products that do not have a marketing authorisation 
and/or might be counterfeit. 
 
International Control  
5.5 In the United States, Federal law placed anabolic steroids in  
Schedule III of the Controlled Substances Act (CSA) in February 1991. 
Subsequently the Anabolic Steroid Control Act of 2004 in the United 
States modified and updated the 1990 law. 
5.6 “The possession or sale of anabolic steroids without a valid prescription is 
illegal. Simple possession of illicitly obtained anabolic steroids carries a 
maximum penalty of one year in prison and a minimum $1,000 fine if this 
is an individual’s first drug offence. The maximum penalty for trafficking is 
five years in prison and a fine of $250,000 if this is the individual’s first 
felony drug offence. If this is the second felony drug offence, the maximum 
period of imprisonment and the maximum fine both double. While the 
above listed penalties are for federal offences, individual states have also 
implemented fines and penalties for illegal use of anabolic steroids”.2
2 2 USA Drug Enforcement Administration 
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6. Epidemiology  
 
Growth of anabolic steroid use in UK 
6.1 An orally active synthetic form of the male hormone testosterone, 17S-
methyltestosterone, and injectable testosterone esters were developed in 
the 1930’s. These rapidly found their way into research and clinical use for 
a variety of conditions including male hypogonadism. These drug products 
were followed by the introduction of novel anabolic steroids (both 
injectable and oral) from the 1950’s onwards that usually exhibited, inter 
alia, an increased ratio of anabolic to androgenic activity (Kochakian, 
1976). The clinical utility of these latter compounds were presumed to be 
in their reduced androgenic activity, and hence could be used more widely 
in women and children for conditions that would benefit from anabolic 
actions (such as cachexia and growth disorders). However, depending on 
type and dose, all anabolic steroids have the potential to induce 
masculinising effects in women and children thus limiting use. In the UK, 
testosterone, its esters and a small number of other types of anabolic 
steroids continue to be used clinically to treat a number of conditions 
including male hypogonadism (Nieschlag, 2006), delayed puberty, 
hereditary angioedema, metastatic breast cancer, and endometriosis 
(British Medical Association & Royal Pharmaceutical Society of Great 
Britain, 2008). In addition, clinical trials are being undertaken for use in 
HIV/AIDS-related wasting syndrome (Johns et al., 2005), as well as a 
male contraceptive (Grimes et al., 2007). 
 
6.2 The potential of anabolic steroids to enhance both physique and sporting 
performance was quickly recognised. The use of anabolic steroids 
therefore grew among sportspersons and some of those attending health 
and fitness clubs. However, there are no reliable data on the early years of 
anabolic steroid use in relation to the UK. 
 
“Determining when steroid use became commonplace within the general 
population of the United Kingdom is problematic, because, until 1992, 
reports were largely anecdotal or informal and limited in scope. It appears, 
however, that by the mid-1960’s the use of steroids was an accepted 
practice in weightlifting and bodybuilding (including those at an amateur 
level). During the 1980’s a number of reports began to appear about the 
use of these drugs in “health and fitness clubs”, supplemented by a small 
informal survey in a gym in the West of Scotland along with a series of 
investigative reports in The Times newspaper that highlighted a “thriving” 
black market in “buying and selling of anabolic steroids … in British 
gymnasiums and health and fitness centres” (Evans-Brown & McVeigh, 
2009).  
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Numbers of anabolic steroid users in UK 
6.3 It is difficult to determine exactly how many people use anabolic steroids 
for non-medical reasons. Although these compounds are controlled under 
the Misuse of Drugs Act 1971 they have never rated a high enforcement 
priority among the many other illicit substances regulated in this way. The 
most comprehensive data for England and Wales are provided by the 
British Crime Survey (Hoare and Moon, 2010). The most recent data for 
2009-2010 report estimates that in the 16-59 year old age group around 
226,000 people reported to “ever” having used anabolic steroids, with 
50,000 users in the past year, and 19,000 in the past month. Although 
these data appear to indicate an increase in anabolic steroid use since 
2008/09 (when 179,000 admitted “ever use” and 17,000 in past year), 
there is no statistical difference in levels of use between years.  
Table 1 summarises the data available for this age group from 1996 to 
2009/2010.There was a statistically significant decline in reported anabolic 
steroid use for ‘lifetime’ use between 1996 and 2009/2010: from 1.1% of 
16–59 year olds in 1996, to 0.7% in 2009/2010.  
Table 1 – Data from British Crime Survey (BCS) on Anabolic Steroid Use 
among 16-59 year olds in England and Wales 
 
1996 1998 2000 2002/ 
2003 
2004/
2005 
2006/
2007 
2008/
2009 
2009/
2010 
% ever 
used 
1.1 1.1 1.0 0.5 0.5  0.6 0.7 
% last  
year 
0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.2 
 
6.4 It is important to note that the survey question on anabolic steroid use has 
changed over this period to include a qualifier. The question on lifetime 
use has been modified from “Have you ever taken anabolic steroids 
(steroids) even if it was a long time ago?” in 2000 to include the qualifier 
“Have you ever taken anabolic steroids (steroids) (not prescribed by a 
doctor) even if it was a long time ago?” In 2001/2002 (and onwards). 
Given the apparent confusion between anabolic steroids and 
corticosteroids — both commonly abbreviated to ‘steroids’ — within the 
general population it is reasonable to speculate that this decrease in 
reported use could actually be (either wholly or partly) due to an artefact 
caused by the change in question, whereby fewer false positives are being 
reported; particularly since this is the only drug question that changed 
during this time period. 
 
6.5 The numbers of women reporting anabolic steroid use are relatively small, 
and there is a clear preponderance of male users, with a ratio of men to 
women reported ranging from 3:1 to as high as 10:1. The number of 
people reporting anabolic steroid use is relatively low by comparison with 
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some other illicit drugs but similar to rates reported for heroin or crack 
cocaine. 
 
6.6 Among younger people (aged 16-24) reported by the BCS in 2009/2010, a 
total of 63,000 reported “ever” having used anabolic steroids; 27,000 used 
anabolic steroids in the last year; and 11,000 used anabolic steroids in the 
last month. Based on data from the 2007/2008 BCS; men again 
outnumbered women by a factor of as much as 10:1. A breakdown of the 
data for 16-59 year olds by age showed that peak reported anabolic 
steroid use occurred in the 25-29 year old sub-group (see Table 2).  
 
Table 2. Data from British Crime Survey (BCS 2007/2008) of percentage 
Lifetime Anabolic Steroid Use in Different Age Groups.  
 
16-19 yr 20-24 yr 25-29 yr 30-34 yr 35-44 yr 45-54 yr 55-59 yr 
0.4 0.8 1.3 0.6 0.6 0.2 0.2 
Table 3. Proportion and estimated number of adults aged 16 to 59 using 
anabolic steroids in the last year (BCS 2009/10).  
 
Proportion and estimated number of adults aged 16 to 59 using anabolic steroids in the last year 
Percentages and numbers  2009/10 BCS
Proportion of adults 
reporting use of anabolic 
steroids in the last year
Number of adults reporting use 
of anabolic steroids in the last 
year
Estimate1 Range2 Estimate1 Range2
Unweighted 
base
% %
16-59 year olds 0.2 0.1 - 0.2 50,000 34,000 - 72,000 26,449
16-24 year olds 0.4 0.2 - 0.7 27,000 14,000 - 50,000 3,465
25-34 year olds 0.2 0.0 - 0.3 13,000 6,000 - 27,000 5,577
35-44 year olds 0.1 0.0 - 0.2 7,000 3,000 - 17,000 7,452
45-59 year olds 0.0 0.0 - 0.1 3,000 1,000 - 12,000 9,955
1. Estimates are based on a small number of users and should be interpreted with caution. 
2. The range is the margin of error around the estimate as these figures are based on data from a sample survey. As the sample 
gets smaller (i.e., for each age breakdown) the margin of error will increase. 
 
6.7 Table 3 above shows the number of adults reporting use of anabolic 
steroids in the last year by age group (2009/10 BCS). The survey 
estimates that around 50,000 16-59 year olds used anabolic steroids in 
the last year; and around half of users (27,000) were in the age group 16-
24 years.   
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6.8 Although the BCS provides the most comprehensive data on the 
prevalence of steroid use it has some limitations when considering steroid 
misuse. For example, being a household survey it does not include 
locations such as halls of residence, prisons or other sites of communal 
living; there is possible confusion in reporting  between medicinal 
corticosteroids and illicit anabolic steroids (noted above); many steroid 
users belong to a closed sub culture who would be reluctant to divulge 
their use to outsiders; and steroid users are likely to be difficult to catch at 
home — most work, with some working evenings, and some can spend a 
high proportion of their time in the gym. 
 
6.9 Despite the apparently reassuring data on general population use of 
steroids from the BCS, which indicate a decrease in steroid use in the past 
decade, there are some signs that this is not the full story. For example, in 
needle and syringe programmes in the North West of England the number 
of new steroid injectors attending these services in the period 1991 to 
2008 has increased more than 10-fold and the total number of steroid 
users had increase more than twenty-fold (McVeigh et al., 2003; Evans-
Brown & McVeigh, 2009; Interagency Drug Misuse Database, 2009)  
 
6.10 It is noteworthy that the “Frank” helpline recorded 250–350 calls in relation 
to anabolic steroids in the period 2003–2007/08.  Further data on both the 
subject matter discussed in these calls as well as the demographics of the 
callers is not available. 
 
Use of Anabolic Steroids by Schoolchildren 
6.11 The BCS data does not report on drug use by children or adolescents 
under the age of 16, but data is available from English and Scottish 
surveys. The National Centre for Social Research have undertaken annual 
surveys of smoking, drinking and drug use among young people (school 
years 7–11) in England in a nationally representative sample of schools.  
Data on drug use are available from 2001 onwards.  Among 11–15 year 
olds 0.5% reported “ever” having used anabolic steroids; 0.4% in the past 
year; and 0.2% in the past month (Fuller and Sanchez, 2010). The 
proportion of anabolic steroid users has remained relatively similar 
between 2001 and 2009, but with approximately twice as many boys 
reporting steroid use as girls. Among the 11–15 year olds surveyed 2% 
had been offered anabolic steroids at some stage (the same level each 
year since 2001). 
 
6.12 In Scotland the Scottish Schools Adolescent Lifestyle and Substance Use 
Survey (Scottish Schools Adolescent Lifestyle and Substance Use Survey, 
2006) has undertaken similar surveys of schoolchildren from 1998 
onwards. In 2006 lifetime use reported by both 13 and 15 year old children 
was 1%, and 1% of those offered had reported use during the past year. 
Unusually, rates of use among girls and boys were approximately equal 
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(the reason for this is unknown). Steroid use remained low by comparison 
with other illicit drugs; 7% of 13 year olds and 26% of 15 year olds 
admitted having used cannabis, and 11% of 15 year olds had used 
stimulants. 
 
6.13 The difficulty of obtaining accurate data on the prevalence of anabolic 
steroid use in young people is illustrated by the review conducted by 
Kanayama et al., (2007) who examined the results of four large national 
surveys on anabolic steroid use conducted in the USA among teenage 
girls. The results were remarkably disparate; one study reported a 
prevalence of only 0.1% whilst others reported figures as high as 7.3%. 
Closer examination of the reasons for such discrepancies suggested that 
the girls in the studies reporting high rates of use had confused anabolic 
steroids with corticosteroids and certain off-the-shelf dietary supplements. 
 
Use of Anabolic Steroids to Enhance Sporting Performance 
6.14 Sportspeople have used anabolic steroids to enhance their performance 
for the past fifty years or more. Such use has gained a high profile 
because of media interest, and persists internationally despite strict rules 
against it and increasingly rigorous random and intelligence-based drug 
testing programmes. The ACMD has not focused on this aspect of steroid 
misuse. In the run up to the 2012 Olympic Games in London a number of 
other groups have been reviewing this issue; these include UK Anti 
Doping, Department of Culture Media and Sport and the Association of 
Chief Police Officers (ACPO) study of “Drugs in Sport”. Chapter 12 of the 
report does, however, note the UK policy response to this. It is hard to 
obtain any reliable estimates of the prevalence of use; even those at the 
highest level of international sport concede that they do not know the true 
prevalence (House of Commons Science and Technology Committee, 
2007). Despite receiving much media attention, the use of anabolic 
steroids in elite sport accounts for only a fraction of the total number of 
steroid users in the general population (Kicman & Gower, 2003; Evans 
Brown & McVeigh, 2008).  
 
Use of Anabolic Steroids for body building and image enhancement 
6.15 Although national surveys indicate a relatively low rate of anabolic steroid 
misuse, this may not give an accurate picture of the higher rates of use 
prevalent among some sections of the community. There continues to be 
significant use of anabolic steroids for cosmetic purposes, not connected 
with any sporting endeavours (Baker et al., 2006; Bolding et al., 2002; 
Lenehan et al., 1996; Williamson, 1991). 
Much of this use is thought to be associated with health clubs and gyms, 
particularly those specialising in bodybuilding, although there is a lack of 
detailed research into the use of anabolic steroid and associated drugs 
within the more mainstream “Lifestyle” gyms. Gyms specialising in 
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bodybuilding were defined as ‘hardcore’ gyms by Lenehan et al., (1996) in 
their prevalence study of anabolic steroid use in gyms in the North West of 
England. The authors categorised gyms into three groups according to the 
equipment/facilities: hardcore, mixed, and fitness. In this study steroid use 
was reported by 29.5% of hardcore gym users (n=29 gyms), 16.0% of 
mixed gym users (n=10 gyms) and 1.5% of fitness gym users (n=4 gyms). 
Lifetime use was 50.7%, 31.9% and 15.1% respectively.  
 
6.16 A survey of gym users in England, Wales and Scotland was 
commissioned by the Department of Health and published in 1993 (Korkia 
& Simpson, 1993). They surveyed 1667 participants in 21 gyms, and 
found that 6% of the men and 1.4% of the women were current users of 
anabolic steroids. Mishkind et al. (1986) have argued that the increasing 
use of anabolic steroids for cosmetic purposes is part of a trend of 
increased awareness of the ‘ideal male body, and changes in behaviour 
as men strive in growing numbers to achieve this mesomorphic muscular 
ideal’. This line of reasoning has received some empirical support from 
work predominately from North America and Australia that has examined 
the structural and personal factors which may shape this ideal, and for 
some individuals, the subsequent use of these drugs in order to attain this 
ideal (Grogan, 2008; Thompson & Cafri, 2007). However, there is limited 
data from the UK (see Grogan, 2008) and care must be taken when 
extrapolating these findings to the UK. 
 
Use of Anabolic Steroids by Professional Groups 
6.17 The ACMD heard anecdotal evidence that anabolic steroids were also 
used by some professional groups to enhance body size and strength. 
This applied particularly to those involved in direct physical contact with 
others as part of their job, including: police, security guards, and night and 
club door supervisors (“bouncers”). No data are available on the number 
of users in this category.  
 
Patterns of Use 
6.18 Anabolic steroids are generally used in patterns called “cycling”. Here the 
drugs are taken for a period of time (for example 6–12 weeks) known as 
an “on” cycle, followed by a similar period of steroid-free training known as 
an “off” cycle. Such a cyclical method is practiced in the belief that it 
prevents 'tolerance' to the steroids, reduce the risk of side effects from 
prolonged use, and allows the hypothalamic-pituitary-gonadal axis (which, 
among other things, controls endogenous testosterone production) time to 
resume normal function. Users also frequently combine several different 
types of anabolic steroids in a process known as “stacking”. Here, two or 
more anabolic steroids are taken at the same time, (using oral and 
injectable products for example). Users believe that stacking will have 
specific additional, or synergistic, effects, although this theory has not 
been scientifically evaluated. 
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7. Anabolic Steroids – Imports, exports and seizures  
 
Imports and exports of anabolic steroids 
7.1 The system for classifying goods for customs purposes is laid down by the 
UN Harmonized System and the EU Tariff Inter-Communautaire. This 
system does not allow for the recording of steroids in more detail than 
‘steroidal hormones’ and only imports from and exports to countries 
outside the EU are required to make a customs declaration, therefore 
consignments coming from or going to other EU Member States cannot be 
counted. Therefore, import/export statistics extracted from Her Majesty’s 
Revenue and Customs (HMRC) sources should be viewed with these 
constraints in mind. 
 
Seizures of Anabolic Steroids – 2005, 2006/7 and 2007/83
7.2 The UK National Drug Strategy directs law enforcement at those drugs 
that are deemed to cause the greatest harm, i.e. Class ‘A’, particularly 
heroin and cocaine. Nonetheless, the national strategy does recognise the 
concerns surrounding the abuse of anabolic steroids and both the police 
and UKBA do seize significant quantities of anabolic steroids. 
 
7.3 The principal issue surrounding the decision whether to seize anabolic 
steroids or not is the lack of an easily determined limit above which there 
is an implicit intent to supply. Table 4 below shows total quantities seized, 
but individual seizures can range from accepted user quantities (being 
brought in on behalf of someone else and therefore liable to seizure) and 
substantial concealments in freight.  
 
Table 4: Seizures of anabolic steroids by Police and UKBA4
Police HMRC/UKBA Total 
2005 
Number of seizures 243 151 394 
Quantity (doses)  853,000 2,481,000 3,334,000 
2006/7 
Number of seizures 433 89 522 
Quantity (doses)  85,000 4,969,000 5,054,000 
2007/8 
Number of seizures 371 126 497 
Quantity (doses)  78,000 6,907,000 6,985,000 
 
7.4 Table 5 notes EU Member states control measures for anabolic steroids.  
 
3 We are not aware of any contemporary data in relation to safe disposal of used injecting 
equipment in this group 
4 For statistical purposes the quantities seized are expressed in doses, using a notional 6.17 
doses to the gramme (this is based on 162mg being the 2005 average weight of a steroid tablet). 
 (source: Home Office Research, Development and Statistics 2007). 
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Table 5. EU Member states control measures for anabolic steroids.
Legal for a person to: Possess without
prescription
Sell without
govt.
authorization
Traffic Use without
prescription
Comments
Austria Y Y Y Y
Bulgaria N N N N
Cyprus N N N N
Czech Republic N N N N
Denmark N N N Y The offence in Denmark exists in possession not use.
Estonia Y N N Y
Finland Y N N Y
France N N N N
There are no concessions in France for personal use
or self-administration. It is a criminal offence for
competition athletes to use doping substances.
Germany Y/N N N Y
Germany has legally prescribed limits defined as ‘not
a small amount’ which define the point beyond which
it is illegal to possess. It is a criminal offence for
competition athletes to use doping substances.
Greece Y N N Y
Hungary Y Y N Y
Ireland N N N Y
Latvia N N N N
Lithuania Y Y N Y
Malta Y N N Y/N
The ban on use applies to competition athletes only.
Portugal Y/N Y Y Y/N
‘Doping’ legislation in Portugal is separate from
controlled drugs legislation and only applies to
competition athletes.
Slovak Republic Y Y/N Y Y
The ban on sale applies only to sales to under-18s
and competition athletes.
Slovenia Y N N Y
Sweden N N N N
United Kingdom Y N N Y
Note: The closest regime that any Member State has to that in the UK is Germany. However the German regime is based on a legally defined
quantity of each drug that constitutes ‘not a small amount’
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8. Chemistry and Pharmaceutical Preparations 
 
8.1 Anabolic steroids are androgens (from the Greek ‘andros’ meaning man 
and ‘gennan’ meaning to produce). The androgenic effects of androgens 
can be generally considered as those associated with masculinisation but 
there are also anabolic effects from these steroid hormones that are 
associated with protein building in skeletal muscle and bone. In men, 
androgens are essential for sustaining reproductive function and they play 
an important role in maintaining skeletal muscle and bone, sex-typical 
cognitive function and a sense of well-being (Christiansen, 2004; 
Mooradian et al., 1987). Testosterone is the most important naturally 
produced androgen, which also has considerable anabolic properties. 
Secretion of testosterone by the healthily functioning testes contributes to 
approximately 95% of the testosterone circulating in the bloodstream 
(Luke et al., 1994; O’Malley et al., 1999). In women, the rate of production 
of testosterone is about a tenth to twentieth less of that in men (0.1 to 0.4 
mg per day compared to approximately 3 to 9mg per day in men).   
 
Figure 1 Examples of commonly used anabolic steroids 
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8.2 Chemical syntheses of analogues of testosterone, related in structure,  
were undertaken by drug companies in an attempt to design steroids with 
enhanced anabolic effects compared to the androgenic effects. In this 
way, it was hoped that the anabolic effects could be harnessed for 
medicinal purposes whilst avoiding the undesirable androgenic effects that 
could cause masculinisation in women and children. Complete 
dissociation (separation) of anabolic from the androgenic effects was 
never achieved, however, and all the anabolic steroids developed have 
androgenic properties to varying degrees. Even so, anabolic-androgenic 
dissociation was considered to be sufficient to warrant many anabolic 
steroids being licensed as medicinal products in the 1960s and 1970s. 
8.3 The efficacy of anabolic steroids in treating patients with considerable 
tissue (protein) breakdown has not proved convincing. By the end of the 
1980s, most anabolic steroids had been withdrawn as licensed products in 
several countries, including the UK, although many anabolic steroids are 
still supplied legitimately in other countries. Anabolic steroids are now 
predominantly limited for the purposes of hormone replacement therapy in 
the testosterone-deficient male (hypogonadism), these being various 
formulations of testosterone and its esters, and some xenobiotic (foreign 
to the body) steroids for the treatment of specific diseases.  
 
8.4 Steroids are sufficiently small to diffuse from the blood stream into cells, 
where they dock into receptors, which are much larger specialised 
molecules. There are different receptors for each class of steroids in target 
tissues, that is, there are specific receptors for androgens, oestrogens 
(female sex hormones), glucocorticoids (helping to regulate blood glucose 
levels and also the body’s overall response to stress) and 
mineralocorticoids (regulate salt balance). Androgen receptors are present 
in cells in reproductive tissues, skeletal and heart muscle, bone, hair 
follicles in the skin, liver, kidney and brain.   
 
8.5 Anabolic steroids activate their receptors through complex molecular 
mechanisms (see Appendix D) to cause changes associated with 
androgenisation and effects on muscle. Usually the body has a natural 
balance between growth (anabolism) and breakdown (catabolism) of cells. 
However, if testosterone is administered chronically in doses sufficient to 
considerably raise testosterone in the blood circulation, this causes a 
swing towards anabolism. For example, there will be growth of skeletal 
muscle and an increase in strength and power, which can also be 
enhanced by taking exercise (Bhasin et al., 1996; Bhasin et al., 2001; 
Woodhouse et al., 2003). Other androgenic effects also are augmented by 
exercise. 
 
8.6 The mechanisms underlying the enhanced anabolic versus androgenic 
effects of some synthetic steroids remain incompletely understood, but are 
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discussed in more detail in Annex C.     
 
8.7 Androgen receptors mediate the effects of anabolic steroids in the 
mammalian brain. Anabolic steroid administration is sometimes associated 
with increased aggression, especially in high-dose users, but increased 
aggression is not a foregone certainty given that the interaction between 
androgens and behaviour in men and women is complex. It is an entirely 
reasonable hypothesis that the athlete and bodybuilder may learn to 
recognise and harness the increase in aggression that may arise with 
steroid use to help drive their training and increase their competitiveness. 
Of note, is that the few research studies (randomised and placebo-
controlled) to investigate the effects of anabolic steroids on mood and 
behaviour have generally failed to demonstrate aggressive behaviour, but 
such studies cannot replicate, for ethical reasons, the high steroid intake, 
and mixtures of drugs, used by some gym-users, which have been 
associated with violent behaviour or ‘roid rage’ (as it is referred to by 
users) (James et al., 2004) 
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9. Harmful effects of anabolic steroids  
 
Background 
9.1 Methodological, ethical and logistical constraints preclude the use of ‘gold 
standard’ randomised controlled trials that administer the high-dose 
polydrug regimens that are common within this community. As a result, 
much of the data on the harmful effects are derived from case 
reports/series and cross-sectional study designs that are observational in 
nature. While clinical case reports and series have associated a number of 
adverse events with the self-directed use of anabolic steroids (i.e. that 
‘there is a reasonable probability that the event may have been caused by 
the drug[s] (Alghabban, 2004)), more research is required to determine if 
the reported associations from studies in this field are independent, 
artifactual (e.g. due to chance or bias), confounded or causal (Alghabban, 
2004). Moreover, many of the studies undertaken in this field to-date have 
serious methodological limitations leading to problems with internal validity 
and generalisability (Evans-Brown et al., 2009). This includes an over-
reliance on the use of self-reported (subjective) measures many of which 
have not been validated. (For further details see Annex E.) 
Harmful Effects of Anabolic Steroids 
9.2 Some of these harmful physical effects (see 9.9) are commonly self-
reported, e.g. acne, endocrine effects, gynaecomastia in males – but 
others are rarer and therefore the causal link to anabolic steroid use is 
equivocal.   
 
9.3 Most of the harmful effects of anabolic steroids are not life-threatening, 
although a small number of deaths have been attributed to liver damage 
associated with long term steroid use. Many, but not all, of the adverse 
effects are reversible on cessation of steroid use. However, there are 
special concerns about the use of anabolic steroids by young people as 
the use of these substances can lead to virilization (see 9.4 for effects on 
females) and, more broadly, potentially disrupt the normal pattern of 
growth and behavioural maturation. 
 
9.4 Adult female steroid users are also exposed to risks such as virilization. 
These can include marked physical effects such as hirsutism, deepening 
of the voice, amenorrhoea/anovulation, clitoral enlargement, atrophy of 
breast tissue, and changes in libido. These effects can be pronounced, 
and, in some cases, permanent. 
 
9.5 Although there is not enough evidence to connect chronic anabolic steroid 
use with substance dependence, the positive psychological effects 
experienced by many users appears to reinforce the continuing use of 
steroids for some users. 
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9. 6 The majority of users inject anabolic steroids (see Annex E). As a 
consequence, they are potentially at risk of a number of serious harms 
that include. However there are limited data on injecting practices in this 
group. Harms include: 1. damage to the injection site as a result of poor 
injecting technique; 2. bacterial and fungal infections (such as localised 
abscesses and systemic infections) as a result of poor injecting technique, 
contaminated drug products, and sharing vials and/or reusing injecting 
equipment; and, 3. Blood-borne viruses (BBV) such as HIV, Hepatitis B 
and hepatitis C as a result of sharing used injecting equipment or sharing 
vials (that have become contaminated through reuse of injecting 
equipment) with others. 
 
9.7 We are not aware of any contemporary data in relation to safe disposal of 
used injecting equipment in this group. Burton (1996) in a study from North 
Wales found that out of ~55 users, 18 passed used equipment to a NSP, 
24 passed the equipment to someone else, 26 put them in the ‘dustbin’, 3 
left them lying around and 4 put them down the drain. Up-to-date research 
is required in this user group. There are limited data on these risks in this 
user group (see Annex E)”. 
 
9.8 In terms of CNS effects, steroid use has been associated with a range of  
psychological and behavioural effects (such as hypomania, mania, 
aggression, violence, depression, and, after ceasing use, suicide) in case 
reports. Although there is not enough evidence to connect chronic 
anabolic steroid use with substance dependence, the positive effects 
experienced by many users (including: increased training capacity; 
strength; enhanced appearance; and, feelings of well being) appear to 
reinforce the continuing use of steroids in some individuals. . 
 
Adverse effects reported to be associated with anabolic steroid use (For a 
more detailed review see Annex E) 
9.9 Acne  
Self-reported acne is a common finding in questionnaire-based studies. 
The measures used have not been validated. There have been some case 
reports that documented severe forms of acne such as acne conglobata or 
acne fulminans in users. 
 
9.10 Androgenic alopecia (male pattern baldness)  
Some users self-report loss of scalp hair in questionnaire-based studies. 
Self-reported increased growth of body hair when using steroids is a more 
common finding. The measures used have not been validated. 
 
9.11 Gynaecomastia  
Gynaecomastia is the growth of the glandular breast tissue in males 
thought to be caused by an imbalance in the ratio of free oestrogen to 
testosterone. In users this could be mediated through the increased 
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peripheral aromatization of aromatizable exogenous steroids to 
oestrogenic metabolites and/or alterations in the transport/binding of 
endogenous oestrogens and testosterone. Many of the drugs commonly 
used by this group (such as growth hormone, human chorionic 
gonadotrophin, spironolactone) have also been clinically associated with 
gynaecomastia. 
 
9.12 Genitourinary 
Many anabolic steroids when used at sufficient dose can suppress 
endogenous testosterone production and spermatogenesis leading to 
transient testicular atrophy and infertility. Data from clinical trials using 
testosterone esters as a male contraceptive, along with case series of 
users, suggest that for some individuals it can take a varying number of 
months for endogenous testosterone production and fertility to recover 
when the drugs are withdrawn. While it is common for users to self-report 
increased libido during an “on” cycle (and to a lesser extent decreased 
libido during an “off” cycle (which in some users could be due to 
suppression of endogenous testosterone production)), these effects have 
not been sufficiently researched. Some users also self-report erectile 
dysfunction both during “on” cycles and “off” cycles. Again these reported 
effects require further research. There has been a case report of prostatic 
cancer in an individual who was a long-term steroid user and a small 
number of case reports of renal cancers in individuals who reported use of 
anabolic steroids. 
 
9.13 Liver  
The use of some types of anabolic steroids, in particular the 17S-alkylated 
compounds, has been associated with hepatic dysfunction and disease in 
clinical populations. In anabolic steroid users there have been some case 
reports of acute liver injury that are associated with the use of oral 17S-
alkylated steroids; while cross-sectional data appears to demonstrate that 
liver function can be impaired in some users. However, the extent of this 
has been questioned by Dickerman et al., (1999) who found that many 
studies failed to use specific markers of liver function and hence failed to 
distinguish between markers of hepatotoxicity and markers of muscle 
damage secondary to high-levels of resistance exercise. Some 
prospective studies have reported no changes in markers of liver function. 
Differences in the study design, participants and drug regimens could 
account for these different findings. There have been a small number of 
case reports of benign liver tumours, peliosis hepatis (blood-filled sacs in 
the liver) and hepatocellular carcinoma reported in the literature in 
individuals who have reported anabolic steroid use. 
 
9.14 Cardiovascular 
The use of anabolic steroids has been associated with a range of both 
acute and chronic cardiovascular pathologies. Much of this data is 
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equivocal (see Annex E). Differences in the study design, participants and 
drug regimens could account for these different findings. 
 
9.15 Musculoskeletal 
There have been a small number of case reports where damage to 
tendons/ligaments have occurred after steroid use. It is thought that this 
could be as a result of disproportionate growth of the muscle compared to 
the tendons/ligaments. There have also been some case reports of 
rhabdomyolysis (breakdown of striated muscle cells). 
 
9.16 Psychological & Behavioural 
While steroid use has been associated with a range of psychological and 
behavioural effects (such as hypomania, mania, aggression, violence, 
depression, and, after ceasing use, suicide) in case reports and some 
studies these effects have not been sufficiently researched. Although there 
is not enough evidence to connect chronic anabolic steroid use with 
substance dependence, the positive effects experienced by many users 
(including: increased training capacity; strength; enhanced appearance; 
and, feelings of well being) appear to reinforce the continuing use of 
steroids in some individuals. It is thought that this can be a particularly 
strong force during an “off” cycle or when ceasing use because 
endogenous testosterone production maybe suppressed, leading to low 
circulating levels. Further research is required to examine these issues.  
 
9.17 Specific concerns for young people 
The use of anabolic steroids can lead to virilization and, more broadly, 
potentially disrupt the normal pattern of growth and behavioural 
maturation. Aside from limited studies examining prevalence, little data are 
available on the use of these drugs by young people. 
 
9.18 Specific concerns for females 
Given the low endogenous levels of testosterone in females, any increase 
(whether through disease or exogenous sources) can lead to virilisation 
which includes: hirsutism, deepening of the voice, 
amenorrhoea/anovulation, clitoral enlargement, atrophy of breast tissue, 
and changes in libido. The impact of these effects can be pronounced, 
and, in some cases, permanent. Little data are available on the use of 
these drugs by this group. 
 
Data from animal studies  
9.19 Studies characterising the actions of many anabolic steroids (including 
compounds that were never commercialised) using in vivo animal studies 
have been extensively reviewed by Krüskemper (1968), Kochakian (1976) 
and Vida (1969). More recently, animal toxicity studies have aimed to 
examine the possible modes of action of anabolic steroids by attempting to 
confirm reported adverse effects in humans. This has included the study of 
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both (serious) physical and behavioural adverse events; such as adverse 
cardiovascular events (Fanton, 2009; Medei et al., 2010), increased 
aggression (Harrison et al., 2000; Melloni et al., 1997) and development of 
dependence (Wood, 2008). Overall these data suggest that, of those 
anabolic steroids tested, high doses could induce such adverse effects. 
 
Nevertheless, there is still a need for a systematic evaluation of data from 
animal toxicity studies with a view to its relevance to humans, particularly 
as there are complex species differences with regards to drug metabolism 
and toxicity.  
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10. Substandard and counterfeit anabolic steroids on the illicit 
market5
Background 
10.1 Counterfeit anabolic steroids are recognised as an issue by the user 
community (Duchaine, 1989; Korkia & Stimson, 1993; Llewellyn, 2009; 
McVeigh & Lenehan 1995). Counterfeit medicinal (drug) products are 
those that are “…deliberately and fraudulently mislabelled with respect to 
identity and/or source. Counterfeiting can apply to both branded and 
generic products and counterfeit products may include products with the 
correct ingredients or with the wrong ingredients, without active 
ingredients, with insufficient (inadequate quantities of) active ingredient(s) 
or with fake packaging” (World Health Organization). However, this 
situation is complicated by the presence on the illicit market of 
(purportedly) legitimate anabolic steroids that are substandard - i.e. “… 
genuine medicines …which do not meet quality specifications set for them 
by [inter]national standards” (World Health Organization, n.d.b.). Both 
substandard and counterfeit anabolic steroids are not based on sufficient 
quality management that is required for medicinal products for use in 
humans (Medicines and Healthcare Products Regulatory Authority, 2007; 
World Health Organization, 2007).  
 
10.2 Limited contemporary data from Australia, Germany, the UK and the US 
suggests that the majority of users obtain their anabolic steroids from the 
illicit market (e.g. Baker et al., 2006; Cohen et al., 2007; Larance et al., 
2005; Parkinson & Evans, 2006; Striegel et al., 2006). While some users 
do obtain drug products through prescription (Cohen et al., 2007; Larance 
et al., 2005; Parkinson & Evans, 2006; Striegel et al., 2006) (although little 
data are available on the proportion of these that would be considered 
clinically appropriate based on current guidelines), or over-the-counter 
(see below), the illicit market is the sole source of some drug products that 
are in high demand by users. Indeed, in the UK many anabolic steroids 
used in ‘stacking’ (Evans-Brown & McVeigh, 2009) are either not available 
as licensed products or may only be licensed as part of veterinary 
medicinal products. 
 
Drug products on the illicit market 
10.3 While there is a paucity of data on the structure of the illicit market, data 
suggest it is comprised from three sources of products: 
 
• Products purportedly manufactured legitimately (typically) in middle-
income countries (such as China, India, Pakistan and some former 
Eastern Bloc countries) where drug regulatory oversight and enforcement 
is weak (World Health Organization, 1999; World Health Organization, 
 
5 Part of this chapter has been reproduced from a publication (Evans-Brown et al., 2009a). 
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2004). Products manufactured and/or packaged in clandestine 
‘underground’ laboratories of varying capacity and quality (Drug 
Enforcement Agency, 2007; Llewellyn, 2007) which, because they exist 
outside of the drug regulatory system, the products cannot demonstrate 
sufficient ‘quality, safety and efficacy’ (Medicine and Healthcare products 
Regulatory Authority, 2007: 4–5).6
• Legitimate products manufactured in high-income countries that are: 
purchased over-the-counter (including internet sales) in countries where 
this practice is lawful or where regulatory oversight and enforcement is 
weak (World Health Organization, 1999; World Health Organization, 
2004); diverted to the illicit market through theft (Bøgeskov, 1998; 
Cameron, 2000; Johansen, 2008); unlawfully resold (e.g. United States 
Attorney’s Office Southern District of Florida, 2009); or 
prescribed/dispensed as a result of fraud (e.g. Drugs and Poisons 
Regulation Group, n.d.; Striegel et al., 2006). 
 
10.4 The proportion each source contributes to the market as a whole is not 
known. Moreover, it is reasonable to assume that the contributions of each 
source are likely to be dynamic both temporally and spatially as a result of, 
inter alia: different policies pursued between (and within) nation-states 
towards restricting the supply, demand and use of these drugs, which will, 
subsequently, result in varying degrees of action by law enforcement and 
drug regulatory authorities; the demand for specific drug products by the 
user community; and, wider economic and social policies, including 
globalisation (Petryna & Kleinman; 2006; World Health Organization, 
2002) and increasing use of the Internet (World Health Organization, 
2002).  
 
Prevalence of substandard and counterfeit anabolic steroids and their 
composition 
10.5 A limited number of studies have examined the composition of anabolic 
steroids obtained from the illicit market. Using convenient samples this 
work has focussed on identification of the active pharmaceutical 
ingredient(s) (API) (Walters, 1990; Perry, 1995; Musshoff, 1997; Thevis, 
2008; Graham et al., 2009), and, more rarely, also quantifying the strength 
of the API (Walters, 1990; Perry 1995). Common findings included: the 
substitution of the API(s) from that stated on the labelling/packaging or the 
inclusion of undeclared APIs (Graham et al., 2009; Perry, 1995; Musshoff 
 
6 It is important to note that some of these labs appear to manufacture products that include 
counterfeit versions of legitimate, licensed, drug products, as well as their own ‘generic’ and 
‘proprietary’ products that do not necessarily appear to fit within the World Health Organization’s 
definition of a counterfeit drug (World Health Organization, 1999). Smaller scale labs appear to 
buy bulk active pharmaceutical ingredients from manufacturers in countries such as China and 
manufacture the finished drug products themselves. 
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et al., 1997; Thevis et al., 2008); no detectable APIs as per those stated 
on the labelling/packaging and as per the analyses undertaken (Perry, 
1995; Graham, 2009); and, APIs that are under-strength (Walters, 1990; 
Perry, 1995) and over-strength (Walters, 1990; Perry, 1995)7. Moreover, 
data from Perry (1995) found large variation between the composition 
(including the strength of APIs) of some products purported to be from the 
same manufacturer, suggesting that visual identification/inspection cannot 
be relied on. Importantly, the published data available on the strength of 
the APIs of these drug products is now more than fourteen years old.  
 
10.6 All these studies used convenience samples and did not adequately 
describe the sampling frame making it difficult to determine how these 
results are representative of the wider market. However, they are broadly 
supported by information from genre publications and the user community 
(Evans-Brown et al., 2009a). There has not been a systematic 
examination of both the prevalence of substandard and counterfeit 
anabolic steroids and their composition 
 
Implications for health 
10.7 Substandard and counterfeit anabolic steroids could affect health in a 
number of ways, including;  
i. Anabolic steroids that are contaminated either biologically, chemically 
or with foreign matter pose a risk to health. This is relevant given that 
many dosage forms are injectable and used in high volume often over 
long periods of time (Medicines and Healthcare Products Regulatory 
Authority, 2007).  
 
ii. While at first glance under strength APIs may not appear to be a 
problem, anecdotally this is believed to have led some users to 
compensate by using much larger ‘doses’. However, given the 
potential variability in the composition from different products (one may 
be over-strength, the next may be under-strength — there is no way of 
knowing with products derived from the illicit market), the next time the 
user may get a product that is over-strength leading to an even higher 
dose being inadvertently used.  
 
iii. The substitution of the API(s) from that stated on the 
 
7 We are also aware of two case reports. Bergman et al., (1993) reported that a vial of ‘Depo-
Testosterone’ (obtained from a user who presented with a gluteal abscess) that was 
contaminated with Pseudomonas organisms (although it is unclear how and when the bacterial 
contamination occurred) and which upon analysis was found to contain “less than 2 mg of 
testosterone per mL when it should have contained 200 mg”; and, van der Kuy et al., (1997) who 
reported the adulteration of an anabolic steroid purporting to be ‘Thai Dianabol’ 
(methandrostenelone) where this API had been substituted for methyltestosterone and the Q2
agonist clenbuterol, the latter being at high strength. Although the methodology of the analyses 
undertaken in these two case reports were not adequately described. 
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labelling/packaging or the inclusion of undeclared APIs means that 
users cannot be assured of the particular API that they are using. This 
is problematic given that individuals seeking low-androgenic 
preparations (particularly women aiming to prevent/limit virilization 
(Korkia et al., 1996)) may unintentionally use a more androgenic API 
(Thevis et al., 2008). 
 
Implications for research 
10.8 Much of the data on the adverse events associated with anabolic steroids 
use (Alghabban, 2004) are derived from case reports/series and cross-
sectional study designs that are observational in nature. Observational 
approaches are likely to remain the main type of research design for some 
time. This is, at least in part, due to the methodological, ethical and 
logistical constraints preclude the use of randomised controlled trials. 
Particular attention should therefore be paid to variables that could affect 
the validity of any such work before it is undertaken (Jenicek, 1999; 
Rothman et al., 2008; Vandenbroucke et al., 2007). 
 
10.9 Data from studies have demonstrated some discordance between self-
reported use of anabolic steroids and that detected through urinalysis 
(Ferenchick, 1996; Sader et al., 2001). Whether this discrepancy is 
unintentional (Geyer et al., 2008) or intentional on behalf of the 
patients/participants is unclear. However, it is apparent that self-reported 
drug use cannot be relied upon (Fendrich et al., 1999; Kidwell et al., 1997; 
Thevis et al., 2008). Moreover, the relatively small number of studies that 
have performed drug identification have not systematically performed drug 
quantification nor examined the composition (including strength of APIs) of 
the drug products being used by the patients/participants. While difficulties 
in this process are evident, it is likely that these methodological limitations 
have weakened the validity and of much of this work.  
 
10.10 The issue of substandard and counterfeit anabolic steroids is likely to 
increase for the foreseeable future if the popularity of these drugs rise, 
coupled to their ease of availability through transnational internet sites 
(purportedly) trading in these products (World Health Organization, 2002). 
Illustrative searches using the term ‘buy anabolic steroids’ (Anonymous, 
n.d.a.) provide an indication of the prevalence and global nature of such 
sites; with data from relatively large Internet-based studies (n=1,955 
(Cohen et al., 2007) and n=500 (Parkinson & Evans, 2006)) in the United 
States reporting that between 52.7%–79.4% of participants had purchased 
anabolic steroids over the Internet (although it is unclear how 
representative these groups are). 
 
10.11 The issue of drug testing and analysis in research studies has become 
more salient given the large number of ‘dietary supplements’ as well as 
‘lifestyle/well-being’ drugs available on the legitimate and illicit markets. 
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This is not only because of the association of adverse events following the 
use of some of these products (see Evans-Brown et al., 2009a), but also 
that some products have been contaminated with APIs such as anabolic 
steroids, centrally acting appetite suppressants, diuretics, and drugs for 
erectile dysfunction. Moreover, some of these APIs were found to be 
present at high strength (see Evans-Brown et al., 2009a). 
 
10.12 This, along with the use of off-the-shelf ‘designer steroid’ supplements 
(Kazlauskas, 2010) — that are marketed as safe(r) and legal alternatives 
to ‘classical’ anabolic steroids — could confound the data if research 
studies do not systematically quantify the use and composition (including 
any contamination) of these products in both users and ‘control groups’ 
(Evans-Brown et al., 2009a). 
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11. Harm reduction 
 
Background 
11.1 Harm reduction can be defined as policies, programmes, services and 
actions that work to reduce the health, social, and economic harms to 
individuals, communities, and society that are associated with the use of 
drugs (Newcombe, 1992). 
 
11.2 Research into preventing, delaying the onset and reducing existing use of 
anabolic steroids is limited. Knowledge-only programmes conducted with 
high-school varsity football players in the United States found that despite 
increasing knowledge of anabolic steroids, these programmes did not alter 
intention to use or actual use; moreover, the authors argue that the use of 
‘scare’ tactics resulted in a trend towards a more positive attitude towards 
use (Goldberg et al., 1990; Goldberg et al., 1991). A randomised 
prospective trial also in the United States focussed on preventing anabolic 
steroid use in adolescent males involved in high school football (Goldberg 
et al., 1996a; Goldberg et al., 1996b; Goldberg et al., 2000) by providing 
education on steroid use along with training in exercise, nutrition and 
communication skills. However, it failed to demonstrate a significant 
difference in the number of individuals taking up anabolic steroid use 
compared with the control group. 
 
11.3 There is no recognised drug treatment provision for anabolic steroid users 
in the UK (National Treatment Agency for Substance Misuse, 2006) and is 
not addressed within the UK Clinical Guidelines for the Management of 
Drug Misuse and Dependence (Department of Health, 2007). 
Furthermore, the use of anabolic steroids is not within the remit of the 
National Treatment Agency for Substance Misuse (National Treatment 
Agency for Substance Misuse, 2006). In the absence of prevention and 
treatment programmes, harm reduction programmes have become the 
mainstay of health interventions. 
 
Do steroid users want harm reduction programmes? 
11.4 Although there are limited data, it appears that there are a significant 
number of users who would welcome appropriate engagement with health 
services (Bolding et al., 1999; Dawson, 2001; Korkia & Stimson, 1993; 
Lenehan et al., 1996; McVeigh & Lenehan, 1995; Pates & Barry, 1996; 
Personal communication from steroid users to ME-B, 2008). Whilst the 
potential barriers to meaningful engagement with this population have 
been recognised by those involved in the provision of National Syringe 
Programmes (NSPs), effective communication has also been identified as 
being critical in the development of appropriate interventions (Sumnall et 
al., 2008). 
 
11.5 NSPs have typically focussed on intravenous injectors, initially those using 
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opiates and more recently those engaged in polydrug use. However, it 
appears that they have been increasingly accessed by those injecting 
anabolic steroids (Korkia & Stimson, 1993; McVeigh et al., 2003). Indeed, 
data from Korkia & Stimson (1993) found that 56% (49/88) of those 
injecting anabolic steroids reported using NSPs as their main source or 
injecting equipment. Korkia & Stimson (1993) also found that 88.8% 
(79/88) of injectors did not experience problems obtaining sterile injecting 
equipment, and 92% (81/88) would use a NSP if it were available to them. 
 
11.6 A study of users in gyms in the North West (Lenehan et al., 1996) found 
that the three main sources of injecting equipment were, in descending 
order of frequency: gym owner/manager; NSPs and friends. The study 
also found that 96.9% of the injectors did not experience problems 
obtaining sterile injecting equipment and 91.7% would (or already had) 
attend(ed) a free NSP for steroid users. 
 
11.7 There is a lack of contemporary data on the sources of injecting 
equipment for steroid users. Data from Merseyside and Chester (McVeigh, 
2003; Evans-Brown & McVeigh, 2009; Interagency Drug Misuse 
Database, 2009) (one of the few areas of the country to have 
systematically recorded injecting equipment transactions since the early 
1990s) have found more than a ten-fold increase in the number of new 
injectors attending NSPs between 1991–2008 and more than a twenty-fold 
increase in the total number of steroid injectors attending these services 
during this time (see section on prevalence). These data provide an 
indication of the importance of NSP in providing injecting equipment to 
steroid users. Moreover, it has been suggested that extensive peer-
distribution networks exist that provide injecting equipment to other users 
(McVeigh et al., 2007; Heron, 2008). 
 
Figure 2 Number of steroid users presenting at Merseyside and Cheshire Needle and 
Syringe Programmes 
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11.8 In a recent report by the National Treatment Agency for Substance 
Misuse, they note that “some [local drug partnerships] had seen an 
exponential rise in steroid use in recent years, with steroid users 
responsible for more than half of needle exchange activity in some 
services. A number of areas had developed, or were in the process of 
developing, services for steroid users. These included needle exchanges 
or mobile needle exchanges in local gyms, outreach and satellite services 
in gyms, specialist clinics at the local harm reduction service and the 
provision of advice and information to steroid users” (National Treatment 
Agency for Substance Misuse, 2006). 
 
Settings for interventions 
11.9 In order to prevent the transmission of blood borne viruses, the ACMD in 
their 1993 report recognised that drug users should have access to sterile 
injecting equipment (Advisory Council on the Misuse of Drugs, 1993, 3):  
“but move beyond the concept of drawing drug users into services 
to develop a broader response, which, above all, incorporates a 
range of early interventions”.  
One particular approach advocated is the use of outreach that “targets … 
those who do not seek (or else do not have easy access to) existing 
services, working with them in their own communities and local settings” 
(Advisory Council on the Misuse of Drugs, 1993). 
 
11.10 Harm reduction programmes aimed at engaging steroid users could be 
delivered in primary and secondary care settings that include: outreach 
services in gyms (inc. mobile NSPs/clinics); needle and syringe 
programmes; pharmacies; GP practice; and secondary care services: 
such as acute (emergency) care services. Indeed, the recently published 
National Institute for Health and Clinical Excellence (NICE) public health 
guidance on NSPs recommends the commissioning of research to 
address how NSP can more effectively engage with anabolic steroid 
users. This specifically included the evaluation of gym-based interventions 
(National Institute for Health and Clinical Excellence, 2009).  
 
Harm reduction resources 
11.11 There are some educational materials, most notably in the form of leaflets 
and booklets, that provide information aimed at educating users and 
reducing harm (this includes information on safer injecting) (Camden 
Primary Care Trust, 2004; HIT, (no .date .available); HIT n.d.b; HIT n.d.c; 
Lifeline, n.d.a; Lifeline, n.d.b; Lifeline, n.d.c; Lifeline n.d.d; Lifeline n.d.e). 
Further, there are also some web-based resources for both users and 
drug workers/health professionals (Centre for Public Health, n.d.). 
However, these compete against information and discussions provided on 
high-profile sites run by those influential in the steroid-using community 
(who may also have financial conflicts of interest). 
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Case studies 
11.12 In response to local need, a small number of specialist services have been 
developed in the UK. These include the Drugs In Sport Clinic and Users’ 
Support (DISCUS) in Tyne & Wear and the Smart Muscle service in Soho, 
London (not currently operating). Furthermore, peer programmes for the 
provision of sterile injecting equipment have also been developed in some 
areas. These are similar to the Steroid Peer Education Project (SPEP) run 
in Victoria, Australia (Delalande et al., 1998; Campbell & Cheryl, 2002), 
where steroid-using peers are involved in the provision of harm reduction 
services. The involvement of peers is viewed as essential to gaining wide 
engagement from this user group8.
Harm reduction interventions 
11.13 While the evidence base for harm reduction within this specific group of 
drug users is scant, general principles of harm reduction from the wider 
drug using population have been adapted for anabolic steroid users and 
are implemented in a number of services (in particular NSPs) across the 
United Kingdom. Based on the limited number of peer reviewed 
publications regarding health interventions for anabolic steroid users 
(Dawson, 2001; Millar, 1994), some basic tenets of harm reduction 
provision have developed. In particular, the prevention of blood borne 
virus transmission (together with a range of other untoward effects of 
injecting) remains a priority. As is the case for most aspects of NSP 
provision in the United Kingdom, these interventions have not been 
evaluated and as highlighted by The Public Health Interventions Advisory 
Committee evidence is particularly lacking in relation to this group of 
injectors: “There is a lack of UK-based research on the effectiveness and 
cost-effectiveness of NSP services in the UK in relation to different groups 
of injecting drug users. There is a particular lack of information on people 
who inject performance- and image-enhancing drugs.” (National Institute 
for Health and Clinical Excellence, 2009).  
 
Vulnerable groups: Young people and women 
11.14 There are a lack of data on young people and women in relation to 
accessing harm reduction programmes. Research is required to explore 
the health needs of these user groups and how these may be best met. A 
significant number of users are young males (18–25) (Lenehan et al., 
1996) who may not perceive themselves as vulnerable (nor may they be 
seen as vulnerable by wider society). Indeed, anecdotal information 
suggests that some younger users may be reluctant to attend NSPs out of 
 
8 While there are a number of services across the United Kingdom offering services to anabolic 
steroid users, we cite four examples of established services, summarised from the conference: 
Performance and Image Enhancing drugs in the 21st Century held in Liverpool on 5th October 
2007, and the reader is directed to Annex F of this report for further details of these. Each 
provides a different approach. The omission of other services that are currently available is in no 
way a reflection of the quality of the interventions they provide. 
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concern of being labelled as an injecting drug user (personal 
communication from steroid users to ME-B, 2008). While the available 
data have demonstrated that the number of women using 
anabolic steroids is small (see section on prevalence; chapter 6), it is 
imperative that those using these drugs have access to services — not 
only access to NSP but also wider health services given the potentially 
permanent virilizing effects of these drugs in this group (see section on 
harms). While research is lacking in this area, there could be gender-
specific barriers that may impede the ability of women users to engage 
with services: in addition to the potential for embarrassment among some 
users due to the virilization of their bodies, users may also feel stigmatised 
as a result of the self-administration of what is regarded as a male sex 
hormone. Further, services may not be set up to provide the specific 
services that women users require.  
 
High-dose polydrug regimens 
11.15 Anabolic steroids are rarely used in isolation but are typically used along 
with a number of ancillary drug including clenbuterol, human growth 
hormone, human chorionic gonadotropin, and insulin (Baker et al., 2006; 
Evans-Brown & McVeigh, 2009 Lenehan et al., 1996) etc. Moreover, there 
is some evidence to suggest that there may be a high prevalence of use of 
cocaine among some groups of anabolic steroid users (McVeigh et al., 
2007). While we are aware that some harm reduction services do reflect 
this polydrug use in the services they provide, overall there is limited data 
on the type of services offered and coverage. 
 
Early identification of problems 
11.16  Data from studies conducted prior to the control of anabolic steroids 
under the Misuse of Drugs Act 1971 found that 32.7% (n=36/110) and 
43% n=~165/384) of current users had informed their general practitioner 
GP) of their use of these drugs (Korkia & Stimson 1993; Lenehan et al., 
1996). However, we are not aware of any contemporary data on this issue. 
It is not known what effect the change in, inter alia, legislation nor the 
increasing use of the Internet to access information has had on health 
seeking behaviours of this group despite simple possession not being an 
offence, anecdotal information suggests that some users believe that it is 
an offence which may deter them seeking help. Furthermore, there are 
limited data on the number of services available to users in the UK that 
would allow them to seek specialist help in relation to their use of these 
drugs. The early identification of problems is paramount to reducing harm. 
Work is required in this area in order to determine the health needs of this 
group and the barriers that they face in engaging with services. 
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12.  Links to sport  
 
Background 
12.1 The increasing use of performance-enhancing substances (‘doping’) from 
1945 onwards by elite athletes (Dimeo, 2007) led to concern by those 
governing sport that their use could damage both the health of the athlete 
and sport. Enmeshed within this were the anabolic steroids which began 
to be used from the 1950s (Dimeo, 2007; Fair, 2000; Hoberman, 2005). 
Ultimately, such concern led to policy measures at both the international 
and national level that were designed to eliminate the use these 
substances in sport. These included, defining ‘doping’, the creation of a list 
of banned substances (and methods), as well as the introduction of 
‘doping control’ (including drug tests) (Dimeo, 2007; House of Commons 
Science and Technology Committee, 2007). As an extension to these anti-
doping activities the World Anti-Doping Agency (WADA) was created in 
1999 with the aims to: 
o To protect the Athletes’ fundamental right to participate in doping-free 
sport and thus promote health, fairness and equality for Athletes 
worldwide, and; 
 
o To ensure harmonized, coordinated and effective anti-doping programs 
at the international and national level with regard to detection, 
deterrence and prevention of doping. (World Anti-Doping Agency 
2008).  
 
12.2 As nation states are not legally bound by the World Anti-Doping Code, the 
UNESCO International Convention Against Doping in Sport (UNESCO, 
2005) was drafted whose ratification, acceptance, approval or accession 
allows national governments to accept WADA and the World Anti-Doping 
Code.  
 
12.3 The United Kingdom has adopted and ratified the UNESCO International 
Convention Against Doping in Sport.  As such the UK Government and 
Devolved Administrations are committed to ‘promote the prevention of and 
the fight against doping in sport’ (UNESCO 2005, 2). These aims are met 
through the framework of the UK National Anti-Doping Policy (UK Anti-
Doping, 2009), issued by the Secretary of State for Culture, Media and 
Sport and counterparts in the Devolved Administrations. The policy is 
based, in part, on the States Parties obligations set out in UNESCO 
International Convention Against Doping in Sport (which in turn is based, 
in part, on the World Anti-Doping Code) and set within the framework of 
existing relevant UK legislation and policy (UK Anti-Doping, 2009a). The 
policy is discharged by UK Anti-Doping, which is the main policy advisor to 
the UK Government in relation to preventing the use of doping in sport and 
the National Anti-Doping Agency for the UK. The policy also lists the roles 
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and responsibilities of its partners, including the Sports Councils (UK Anti-
Doping, 2009a:13–14); National Governing Bodies (UK Anti-Doping, 
2009a:15–24), and the National Anti-Doping Panel (UK Anti-Doping, 
2009a:25). Broadly the objectives of UK Anti-Doping (UK Anti-Doping, 
2009a) are: 
 
o To prevent and deter doping through education programmes about the 
effects of, and rules related to, doping and the testing regime to which 
athletes will be subject. 
 
o To take on existing testing and education responsibilities from UK 
Sport, whilst also being granted significant new powers to ensure 
Britain is best-placed to tackle doping in sport in the run-up to the 
London 2012 and beyond. 
 
o To undertake ‘doping control’ (UK Anti-Doping, 2009b; UNESCO, 
2005:3), including: 
 
o To test athletes for performance-enhancing substances and/or 
methods on the Prohibited List (UK Anti-Doping, 2009b). 
 
o Case presentation and disposal against an athlete or support 
personnel who violate the UK Anti-Doping Rules (UK Anti-Doping, 
2009b). Therein, Anti-Doping Rule Violations (subject to sanctions) for 
an athlete (and where relevant, athlete support personnel) include, 
inter alia, use, attempted use, possession, trafficking or attempted 
trafficking, administration or attempted administration of a substance or 
method on the Prohibited List (UK Anti-Doping, 2009b; WADA 2009). 
 
o To collaborate and exchange intelligence with law enforcement 
agencies to interfere with the supply of performance-enhancing 
substances and identify athletes or athlete support personnel that 
might be involved in doping. 
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13.  Recommendations 
 
Legal status 
13.1 In the United Kingdom, anabolic steroids are classified under the Misuse 
of Drugs Act 1971 as Class C substances; this puts them in the same 
Class as buprenorphine and ketamine. Anabolic steroids are placed in 
Part 2 of Schedule 4 to the Misuse of Drugs Regulations 2001 (as 
amended). 
 
Licit anabolic steroids can only be sold by pharmacists through a doctor's 
prescription. It is legal to possess or import steroids as long as they are 
intended for personal use and in a medicinal form. However, the 
possession or importing with intent to supply is illegal and could lead up to 
14 years in prison and an unlimited fine.  
 
Overall, the ACMD consider that the legislative framework should be 
strengthened primarily through greater enforcement (not legislative 
changes) with a focus on importation via on-line ordering. In addition, the 
ACMD recommend (see recommendation 4) that further restrictions 
should be placed on personal importation by having personal custody 
requirements.  
 
Recommendation 1 
13.2 Anabolic steroids should continue to be controlled as Class C drugs under 
the Misuse of Drugs Act 1971. The ACMD consider that the evidence base 
regarding the harms of anabolic steroids does not support a change in 
classification status. The ACMD consider that the harms associated with 
anabolic steroid use are commensurate with other Class C drugs.  
 
Recommendation 2 
13.3 The ACMD do not believe the term ‘medicinal product’ assists in the 
enforcement or legal framework for anabolic steroids under the Misuse of 
Drugs Act 1971. The ACMD consider that the term ‘medicinal product’ 
should be removed from the legislation as the term does not serve a 
recognised purpose (reference paragraphs 5.3 – 5.5).  
 
Recommendation 3 
13.4 The ACMD consider that although a small number deaths have been 
attributed to liver damage associated with steroid use, the health related 
harms associated with the use of anabolic steroids, are not of the severity 
of those associated with a number of other Class C drugs e.g. gamma-
hydroxybutyrate, or ketamine –which can be life threatening in overdose, 
or benzodiazepines which carry dependence liability.  For this reason the 
ACMD continues to believe that it should not be an offence under the 
Misuse of Drugs Act 1971 to simply possess anabolic steroids for personal 
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use. Criminal prosecution should be limited to illicit steroid dealers, 
suppliers, manufacturers and traffickers who profit from this trade. 
Retaining the lack of a possession offence emphasises the ongoing need 
to focus on public health. The ACMD concludes that improved tailored 
intervention and education messages aimed at anabolic steroid users 
would be more effective than criminalising users and further pushing the 
issue underground.  
 
Restrict the method of importation to personal custody  
13.5 The current legal framework permits imports (or exports) of steroids for 
self-administration. There is no requirement that the drugs have to be 
personally transported/ imported. This can pose problems where steroids 
are imported via post or courier (i.e. items are unattended in transit). 
Border force officials can be unable, in these circumstances, to determine 
whether the products are for personal use as they are unable to question 
the importer at point of entry and may not necessarily be able to identify 
the importer from the import declaration. To establish whether imported 
items are for personal use will necessarily involve a potentially costly 
investigation by UK Border Force officials as to the circumstances in which 
the drugs are being imported. 
 
Recommendation 4 
13.6 Further restriction should, after consideration in the context of the EU 
legislation, be placed on the importation, and exportation, exemption, 
namely personal custody on importation.  
 
13.7 Anabolic steroids are currently freely available for on-line ordering by 
various web sites. There is no restriction on these and little or no quality 
control. Imposition of a personal custody requirement for importation 
would make such purchases illegal.  
 
Harm Reduction Measures  
13.8 There is very little centrally co-ordinated information is available on harm 
reduction and users sometimes receive ambiguous information in relation 
to harms associated with anabolic steroids. 
 
Recommendation 5 
13.9 There is a need for widespread, credible, information and advice for users 
to counteract the flood of mis-information provided by various web sites 
that actively promote anabolic steroid use.  Such information should be 
available in, for example, GP surgeries, clinics, gyms, NEP’s and PCT’s 
settings etc. The ACMD recommend that FRANK would be a suitable 
vehicle for this campaign. However, promulgation of the information 
should be wide enough so as to reach users in all settings. Gym based 
organisations (e.g. the Fitness Industry Association (FIA), Body Building 
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Federation and other professional bodies) should be encouraged to be 
involved.  
 
Recommendation 6 
13.10 The ACMD recommend there should be greater focus on users of 
image/performance enhancement substances, including anabolic steroid 9
and human growth hormones, who present to Needle Exchange Schemes; 
this may include dedicating special sessions to cater for 
image/performance enhancement substance users, who may be reluctant 
to associate/mix with mainstream opioid user groups. The ACMD believe 
the National Treatment Agency should afford this issue greater 
recognition. The ACMD considers that a concerted effort should be made 
to address current and future levels of blood borne viruses’ among users 
of anabolic steroids and associated substances.   
 
13.11 The ACMD recognises the contribution of those services, although limited 
in number, dedicated to anabolic steroid users, and the range of services 
they afford to anabolic steroid users.   
 
Recommendation 7 
13.12 There should be greater awareness of current centres for support; e.g. 
DISCUS and Smart Muscle- and additional centres of good practice 
should be developed to raise the profile of the issues associated with 
anabolic steroid use and the knowledge of individuals involved with harm 
reduction should be improved.   
 
Research  
 
Recommendation 8 
13.13 Improved data on users should be gathered to better inform interventions. 
Specifically, this data gathering should be centred on gyms and health 
clubs and includes: numbers using; duration of time that people use them 
for and other such patterns of behaviour.  
 
Recommendation 9 
13.14 As the data is lacking as to the specific anabolic steroids that are used, 
NEP’s should collate data on what users are actually administering. 
Chemical analysis of used vials could assist this objective.   
 
Recommendation 10 
13.15 The British Crime Survey is not constructed to adequately assess the 
prevalence of anabolic steroid use. Other channels should be utilised to 
 
9 Including human growth hormones and other performance enhancing associated substances; 
as users may use anabolic steroids, human growth hormones and other associated substances in 
conjunction with one another; therefore services should cater for the users of all performance 
enhancing substance.     
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gain better data on prevalence. A survey of the UK general population to 
focus on particular sub-groups – children and young people should be 
constructed. This should be designed to gather a better national profile of 
anabolic steroid use with the purpose of considering targeted health 
interventions.    
 
Recommendation 11 
13.16 A national survey and survey of gym users should allow better data to be 
gathered on the prevalence of blood borne viruses among anabolic steroid 
users.  
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